Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visit Frequency and Antidepressant Response in MDD
NCT03812588Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Escitalopram oxalate oral solution in major depressive disorder (MDD) (4 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Hamilton Rating Scale for Depression 24-Item at 8 weeks. Started Jan 2019; status: completed.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03812588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812588.